We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ADPT market cap is 946.72M. The company's latest EPS is USD -1.5263 and P/E is -4.17.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 37.65M | 48.93M | 37.92M | 45.78M | 41.87M |
| Operating Income | -57.19M | -47.82M | -50.96M | -45.64M | -48.76M |
| Net Income | -57.7M | -47.81M | -50.3M | -69.44M | -47.51M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 85.07M | 98.38M | 154.34M | 185.31M | 170.28M |
| Operating Income | -78.39M | -152.82M | -208.97M | -200.19M | -201.61M |
| Net Income | -69.57M | -146.23M | -207.28M | -200.19M | -225.25M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 791.46M | 764.54M | 717.68M | 661.13M | 620.32M |
| Total Liabilities | 367.51M | 368.57M | 356.05M | 352.86M | 345.56M |
| Total Equity | 423.95M | 395.97M | 361.64M | 308.28M | 274.77M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 912.3M | 1.12B | 923.34M | 856.62M | 661.13M |
| Total Liabilities | 341.26M | 373.15M | 319.24M | 392.52M | 352.86M |
| Total Equity | 571.04M | 743.27M | 604.1M | 464.1M | 308.28M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -59.15M | -82.71M | -129.39M | -156.32M | -38.35M |
| Investing | 62.98M | 100.3M | 126.44M | 129.65M | 44.51M |
| Financing | 672k | 2.14M | 2.16M | 2.25M | 44k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 205.4M | -149.68M | -192.73M | -183.95M | -156.32M |
| Investing | -481.7M | -117.04M | 181.21M | 2.91M | 129.65M |
| Financing | 319.92M | 293.59M | 27.15M | 132.27M | 2.25M |
| Market Cap | 946.72M |
| Price to Earnings Ratio | -4.17 |
| Price to Sales Ratio | 5.51 |
| Price to Cash Ratio | 14.43 |
| Price to Book Ratio | 3.04 |
| Dividend Yield | - |
| Shares Outstanding | 147.58M |
| Average Volume (1 week) | 1.24M |
| Average Volume (1 Month) | 1.53M |
| 52 Week Change | 36.78% |
| 52 Week High | 6.70 |
| 52 Week Low | 2.28 |
| Spread (Intraday) | 0.01 (0.16%) |
| Company Name | Adaptive Biotechnologies Corporation |
| Address |
711 capitol way s ste 204 olympia, washington 98501 1267 |
| Website | https://www.adaptivebiotech.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
